By Professor Alan Trounson (Cartherics)2023-11-17T16:00:37
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, is this a valid belief at the present stage of development of the immune therapy field?
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-26T13:58:00Z
2023-03-08T16:29:20
Sponsored by Bio-Techne
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2023-03-03T14:06:14
Sponsored by Bio-Techne
2024-02-01T11:52:50
Sponsored by Leica Microsystems
2023-07-11T16:13:06
Sponsored by Agilent
2024-02-01T12:06:43
Sponsored by Leica Microsystems
Site powered by Webvision Cloud